ResMed Files 8-K on Financial Results & Other Events
Ticker: RSMDF · Form: 8-K · Filed: Jan 24, 2024 · CIK: 943819
| Field | Detail |
|---|---|
| Company | Resmed Inc (RSMDF) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.004, $0.48 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-update
TL;DR
**ResMed just dropped an 8-K with financial results, so get ready for potential stock movement.**
AI Summary
ResMed Inc. filed an 8-K on January 24, 2024, to announce its results of operations and financial condition, along with other events. This filing, under Items 2.02 and 8.01, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers crucial insights into the company's recent profitability and overall financial health, which can influence stock valuation and future investment decisions.
Why It Matters
This filing provides investors with the latest financial performance data for ResMed Inc., which is essential for evaluating the company's health and making informed investment decisions.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial results and other events, which is standard for public companies and does not inherently introduce new risks.
Analyst Insight
Investors should review the full content of the 8-K filing, once available, to understand the specific financial results and other events reported by ResMed Inc. This will allow for a detailed assessment of the company's performance and potential impact on its stock.
Key Players & Entities
- ResMed Inc. (company) — the registrant filing the 8-K
- January 24, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for ResMed Inc.
- 001-15317 (company) — Commission File Number for ResMed Inc.
- 9001 Spectrum Center Blvd. San Diego, California 92123 (company) — address of principal executive offices for ResMed Inc.
FAQ
What is the purpose of this 8-K filing by ResMed Inc.?
The purpose of this 8-K filing by ResMed Inc. is to report on its results of operations and financial condition, as well as other events, as indicated under Item 2.02 and Item 8.01 of the filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 24, 2024, which is also the date of the report.
What is ResMed Inc.'s state of incorporation and Commission File Number?
ResMed Inc. is incorporated in Delaware, and its Commission File Number is 001-15317.
Under which sections of the Securities Exchange Act of 1934 is this report filed?
This report is filed under Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the trading symbol and exchange for ResMed Inc.'s Common Stock?
ResMed Inc.'s Common Stock trades under the symbol RMD on the NYSE (New York Stock Exchange).
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-01-24 16:06:01
Key Financial Figures
- $0.004 — nge on which registered Common Stock, $0.004 par value RMD NYSE Indicate by che
- $0.48 — eclared a quarterly cash dividend of US $0.48 per share. The dividend will have a rec
Filing Documents
- d685328d8k.htm (8-K) — 26KB
- d685328dex991.htm (EX-99.1) — 259KB
- g685328g0124091202206.jpg (GRAPHIC) — 2KB
- 0001193125-24-014223.txt ( ) — 430KB
- rmd-20240124.xsd (EX-101.SCH) — 3KB
- rmd-20240124_lab.xml (EX-101.LAB) — 18KB
- rmd-20240124_pre.xml (EX-101.PRE) — 11KB
- d685328d8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 24, 2024, we issued the press release furnished as Exhibit 99.1. The press release describes the results of our operations for the quarter ended December 31, 2024. The information furnished in this Current Report on Form 8-K under Item 2.02 and the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On January 24, 2024, we announced that our board of directors declared a quarterly cash dividend of US $0.48 per share. The dividend will have a record date of February 8, 2024, payable on March 14, 2024. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Instruments trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be February 7, 2024, for common stockholders and for CDI holders. ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 7, 2024, through February 8, 2024, inclusive.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibits: Description of Document 99.1 Press Release dated January 24, 2024, regarding results of operations 104 Cover Page Interactive Data File (embedded within the Inline XBRL, document) -2-
SIGNATURES
SIGNATURES We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934. Date: January 24, 2024 RESMED INC. (registrant) By: /s/ Brett Sandercock Name: Brett Sandercock Its: Chief Financial Officer -3-